Markers of Vascular Aging and Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

— MAVASCOR  

Official title:

Markers of Vascular Aging and Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02857387
• Other study ID #: PO15043
• Status: Completed
• Phase: N/A
• Start date: October 2015
• Est. completion date: August 27, 2018

Study information

• Verified date: October 2018
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atherosclerosis and aging are associated to the raise of biochemical alterations of proteins grouped under the name of " non-enzymatic post-translational modifications ". They often correspond to the irreversible binding of glucose or other oses (glycation) or urea derivatives (carbamylation) on proteins and lead to the formation of complex compounds (post-translational modifications derived products, PTMD) that can accumulate in tissues and be responsible for deleterious effects. The specific role of these compounds in the pathophysiology of aging and atherosclerosis remains unknown, as are the molecular and cellular mechanisms implicated.

This project is based on the hypothesis that non-enzymatic post-translational modifications may cause changes in the genesis of complication of coronary atherosclerosis and that PTMD could therefore constitute relevant biomarkers in this specific clinical situation.

To explore these potential new biomarkers, the investigators designed a study in patients having experienced an acute coronary syndrome and followed during a year. The concentrations of PTMD assayed at 0, 1, 3, 12 months, will be correlated to clinical (severity and evolution) and paraclinical (cutaneous autofluorescence) data and the effect of cardiac rehabilitation will be assessed.

This should help to identify new (and non-traditional) biomarkers of coronary heart disease and determine some of the implicated pathophysiological mechanisms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: August 27, 2018
• Est. primary completion date: August 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• acute coronary heart syndrome

• included during hospitalization, usual cardiologic follow-up planned in Reims university hospital

Exclusion Criteria:

• <18yo

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Intervention

Biological:
• blood sample withdrawn

Locations

Country	Name	City	State
France	Chu Reims	France	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-translational modifications of Proteins quantification assessed by Liquid chromatography-mass spectrometry		up to 1 year